Iscalimab

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NameIscalimab
Drug Alias NameNVP-CFZ533OM11-62-MFCFZ-533
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor receptor superfamily member 5 inhibitors
TargetsTumor necrosis factor receptor superfamily member 5
Therapy Area/IndicationsRejection of renal transplantationDiabetes Mellitus, Type 1Lupus Erythematosus, Systemic +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[38] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesNovartis Pharma AgNovartis Pharma Stein AgChina Novartis Institutes For Biomedical Research Co Ltd
Inactive CompaniesN/A
Active IndicationsRejection of renal transplantationDiabetes Mellitus, Type 1Lupus Erythematosus, Systemic +[7] 
Inactive IndicationsGraves DiseaseArthritis, RheumatoidMyasthenia Gravis +[4] 

Other Information

ATC CodeN/A
Related LinksN/A